Phase 3 study investigating the efficacy and safety of roxadustat for treatment of anemia in patients with lower risk Myelodysplastic Syndrome (MDS) and low Red Blood Cell (RBC) transfusion burden.

Non-Small Cell Lung Cancer

The KEYNOTE B36 study is a Phase 2 pilot, single-arm, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Study patients use the device concomitant with pembrolizumab for...

Multiple Myeloma

Disease registry encompassing the care of patients with multiple myeloma on panobinostat. Participants will describe current treatment patterns and characterize adverse events in the first or later lines of therapy. Outcomes reported in RECOMM Registry

Non-small Cell Lung Cancer

Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pembrolizumab for stage IIIB or IV non-small cell lung cancer...

Non-Small Cell Lung Cancer

Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard-of-care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.